Resistance management of avatrombopag

Avatrombopag (Avatrombopag) is a medicine used to treat certain types of thrombocytopenia. Drug resistance can develop in some patients, rendering the drug less effective. To deal with the problem of drug resistance of avatrombopag, you can consider adjusting the dosage, combination therapy, etc. However, everyone has a different constitution and has different drug resistance reactions. If you experience discomfort after using avatrombopag, please inform your doctor in time.

If a patient is no longer sensitive to regular doses of the drug, doctors may increase the dose to get better results, as sometimes increasing the dose of avatrombopag can improve its effectiveness. Your doctor may also recommend combining avatrombopag with other medications or treatments to make your treatment more effective. Certain causes may lead to resistance to avatrombopag. Treating the underlying disease or managing other related problems may help restore sensitivity to avatrombopag. If patients develop resistance to avatrombopag, they should consult their doctor or professional medical team promptly. They can assess the situation and provide personalized advice and treatment options.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for eligible patients. The price of a common specification of 20mg*15 tablets may be more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).